CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.

Key facts

Study ID

NCT00482521

Run by

Case Comprehensive Cancer Center

People needed

42

Starts

2007-03-01

Expected to finish

2012-08-01

Last updated by the study team

2012-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
• Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.